Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JH013
- Development stage
- Phase 1
- Lead developer
- Biotech Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
JH013 is a monoclonal antibody currently in Phase 1 clinical development. It is being investigated for the treatment of immune system diseases, eye diseases, and mouth and tooth diseases. The primary active indications under study include Sjogren's syndrome, hematologic neoplasms, and systemic lupus erythematosus. The drug is administered via subcutaneous injection. As of now, the specific molecular target and mechanism of action have not been publicly disclosed. The developer and main sponsor for clinical trials is Biotech Pharmaceutical Co., Ltd., with Ambotek Pharmaceutical Co., Ltd. also listed as a collaborator in at least one trial[1][3][4][7].
Beyond the preview
Go deeper on JH013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JH013.